Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Epelsiban

Generic Name: Epelsiban

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₃₈N_₄O_₄

CAS Number: 872599-83-2

Unique Ingredient Identifier: T2EZ19HX73

Overview

Epelsiban has been investigated for the treatment of Premature Ejaculation.

Background

Epelsiban has been investigated for the treatment of Premature Ejaculation.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

Phase 2

Withdrawn

Posted: 2016/06/09

Sponsor:GlaxoSmithKline

ID:NCT02794467

Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers

Phase 1

Completed

Posted: 2016/03/09

Sponsor:GlaxoSmithKline

ID:NCT02703181

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers

Phase 1

Completed

Posted: 2014/10/06

Sponsor:GlaxoSmithKline

ID:NCT02257359

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

Phase 1

Terminated

Posted: 2014/08/11

Sponsor:GlaxoSmithKline

ID:NCT02213029

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy